Almirall Takes a Leap into Dermatology Digital Health Innovation

AlmirallAlmirall, S.A. (ALM) has launched its first call for innovation to start-ups focused on dermatology digital health. This initiative is the first step in the creation of an accelerator programme called the Digital Garden, powered by Almirall and strengthens the company's commitment to digital innovation based on developing services and solutions to tackle some of the present and future dermatological challenges. The call has been presented during the first Barcelona Health Hub (BHH) Summit, sponsored by Almirall, which has taken place at BHH’s headquarters, located in Barcelona, Spain.

The Digital Garden will begin its journey supporting up to five start-ups chosen after a selection process that will end on November 14th at Almirall's event in Berlin at Frontiers Health 2019, a leading global event on digital health innovation of which Almirall is a sponsor.

Francesca Wuttke, Chief Digital Officer of Almirall, explains the importance of this project "I am so pleased and excited to announce the launch of the Digital Garden powered by Almirall, and to do so at the BHH Summit. In fact, the five start-ups selected during Frontiers of Health will have access to a nine-month acceleration program based in the BHH headquarters, among other important benefits."

Digital Garden's selection process

Interested start-ups can apply at almiralldigitalgarden.com, where they will also find the program's inclusion criteria and offerings. Following a review of the applicants, Almirall will make a shortlist of 10 companies that will be invited to Frontiers Health 2019 to pitch their business models at an Almirall sponsored event that will take place on Thursday 14th of November. The five winning project teams will begin a nine-month acceleration program in January at the BHH headquarters, with the goal of graduating them into venture capital funding. The program will include introductions to investors as well as an investor day.

In addition to the acceleration program, the five chosen start-ups will receive a number of key incentives, including up to a €50K grant that is determined based on a bespoke gap analysis of the start-up and achievement of certain milestones. In addition, they will receive mentoring from top pharma industry experts from all specialties and program stages; and will have the opportunity to leverage leading hospitals in Barcelona as a test bed for digital pilots, with potential access to HCPs and patients; the potential to collaborate on actual Almirall projects; and have access to Almirall's communication and PR networks to promote their projects, among others.

"Embracing technologies to better access data to empower patients"

Francesca Wuttke is one of the four BHH Ambassadors, highly renowned professionals in digital health that are dedicated and aligned with the goals of the Barcelona Health Hub. They are collaborating to increase awareness in digital health and in a global recognition of the BHH. During the BHH Summit 2019, she moderated one of the panels entitled "Embracing technology to better access data to empower patients". CEOs from three of the start-ups that are sharing BHH co-working space have discussed growing trends in the pharmaceutical industry. Increasingly, pharma companies are collaborating with start-ups to improve the strength of their data and bring efficiencies with regard to time and cost. The panellists have also shared their views about the potential of new technologies in the era of Real World Data and Real World Evidence, the impact of regulation and the future of partnerships between big companies and start-ups with its implicit challenges and lessons learned.

According to Francesca Wuttke, "Medical dermatology is a representative example of the potential of patient centric digital health. The Digital Garden, powered by Almirall can be seen as a case study of both the recent and rapid development in this space and the huge potential of this new digital revolution in medicine."

About Almirall

Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying Science to provide medical solutions to patients and future generations. Our efforts are focused on fighting skin health diseases and helping people feel their best. We support healthcare professionals in continuous improvement, bringing our innovative solutions where they are needed.

The company, founded almost 75 years ago and with headquarters in Barcelona, is listed on the Spanish Stock Exchange (ticker: ALM). Almirall has become a key element of value creation to society according to its commitment with its shareholders and its decision to help others by understanding their challenges and using Science to provide solutions for real life. Total revenues in 2018 were 811 million euros. Almirall has more than 1,800 employees.

Most Popular Now

SPARK TSL Acquires Sentean Group

SPARK TSL is acquiring Sentean Group, a Dutch company with a complementary background in hospital entertainment and communication, and bringing its Fusion Bedside platform for clinical and patient apps to...

ChatGPT Extracts Data for Ischaemic Stro…

In an ischaemic stroke, an artery in the brain is blocked by blood clots and the brain cells can no longer be supplied with blood as a result. Doctors must...

Herefordshire and Worcestershire Health …

Herefordshire and Worcestershire Health and Care NHS Trust has successfully implemented Alcidion's Miya Precision platform to streamline bed management workflow across seven community hospitals in Worcestershire. The trust delivers community...

A Shortcut for Drug Discovery

For most human proteins, there are no small molecules known to bind them chemically (so called "ligands"). Ligands frequently represent important starting points for drug development but this knowledge gap...

New Horizon Europe Funding Boosts Europe…

The European Commission has announced the launch of new Horizon Europe calls, with a substantial funding pool of over €112 million. These calls are aimed primarily at pioneering projects in...

Cleveland Clinic Study Finds AI can Deve…

Cleveland Clinic researchers developed an artficial intelligence (AI) model that can determine the best combination and timeline to use when prescribing drugs to treat a bacterial infection, based solely on...

New AI-Technology Estimates Brain Age Us…

As people age, their brains do, too. But if a brain ages prematurely, there is potential for age-related diseases such as mild-cognitive impairment, dementia, or Parkinson's disease. If "brain age...

Radboud University Medical Center and Ph…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Radboud University Medical Center have signed a hospital-wide, long-term strategic partnership that delivers the latest patient monitoring...

With Huge Patient Dataset, AI Accurately…

Scientists have designed a new artificial intelligence (AI) model that emulates randomized clinical trials at determining the treatment options most effective at preventing stroke in people with heart disease. The model...

GPT-4, Google Gemini Fall Short in Breas…

Use of publicly available large language models (LLMs) resulted in changes in breast imaging reports classification that could have a negative effect on patient management, according to a new international...

ChatGPT fails at heart risk assessment

Despite ChatGPT's reported ability to pass medical exams, new research indicates it would be unwise to rely on it for some health assessments, such as whether a patient with chest...

Study Shows ChatGPT Failed when Challeng…

With artificial intelligence (AI) poised to become a fundamental part of clinical research and decision making, many still question the accuracy of ChatGPT, a sophisticated AI language model, to support...